Typhocon – Typhoid Vi Conjugate Vaccine

Indication: Active immunization against infection caused by Salmonella typhi in infants, children, adolescents, and adults aged 6 months to <45 years.
Pharmacology: Clear, colorless solution free from visible particles. Contains 25 µg of Typhoid Vi polysaccharide conjugated to CRM197 carrier protein. Sodium chloride and phosphate buffer act as diluents; 2-phenoxyethanol is added as preservative. Meets ILP & WHO requirements.
Dosage & Administration:
- Single 0.5 mL IM injection.
- For children ≥2 years, adolescents, and adults: inject into deltoid muscle.
- For infants 6 months to <2 years: inject into anterolateral thigh muscle.
- Do not inject into gluteal area or near nerve trunks.
Interaction: No clinical data on co-administration. Do not mix with other vaccines or medicinal products.
Contraindications: Hypersensitivity to components, pregnancy & lactation, fever or severe infection.
Side Effects:
- Local: Injection site pain (4.5%), erythema (0.64%), swelling (0.32%).
- Systemic: Pyrexia (2.35%), vomiting (0.96%), headache (0.64%), fatigue (0.64%), arthralgia (0.32%), rash (0.32%).
- Usually mild, resolving within 2–3 days. No serious adverse events reported.
Pregnancy & Lactation: Safety not established; unknown if secreted in breast milk.
Precautions & Warnings:
- Do not administer IV, intradermally, or subcutaneously.
- Protects only against Salmonella typhi, not paratyphi or other non-typhoidal strains.
- Epinephrine injection (1:1000) must be available for anaphylaxis.
- Keep under medical supervision for ≥30 minutes post-vaccination.
Therapeutic Class: Vaccines, Anti-sera & Immunoglobulin
Storage: Store at +2°C to +8°C. Do not freeze. Discard if frozen. Shake well before use. Keep out of reach of children.